Travere Therapeutics, Inc. (RTRX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Innoviva, Inc.

Travere Therapeutics, Inc.

Collegium Pharmaceutical, Inc.

Amneal Pharmaceuticals, Inc.

Viridian Therapeutics, Inc.

NewAmsterdam Pharma Co. NV

Arcturus Therapeutics Holdings, Inc.

REGENXBIO, Inc.

Pharvaris NV

POINT Biopharma Global, Inc.

Intercept Pharmaceuticals, Inc.

Why is Travere Therapeutics, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate 3.13% of over the last 5 years

With a growth in Operating Profit of 1357.28%, the company declared Very Positive results in Mar 26

The company has declared positive results for the last 7 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD 39.61 MM
NET SALES(HY) At USD 256.89 MM has Grown at 64.13%
NET PROFIT(HY) Higher at USD -58.59 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 282.72%, its profits have risen by 80.1%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating performance in long term as well as near term

Along with generating 282.72% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Travere Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Travere Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Travere Therapeutics, Inc.

282.72%

8.87

74.27%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

19.87%

EBIT Growth (5y)

3.13%

EBIT to Interest (avg)

-17.42

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.91

Sales to Capital Employed (avg)

0.63

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

21.89

EV to EBIT

-39.93

EV to EBITDA

-1207.12

EV to Capital Employed

22.88

EV to Sales

5.11

PEG Ratio

Dividend Yield

ROCE (Latest)

-57.30%

ROE (Latest)

-43.77%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 39.61 MM

NET SALES(HY)

At USD 256.89 MM has Grown at 64.13%

NET PROFIT(HY)

Higher at USD -58.59 MM

ROCE(HY)

Highest at -69.38%

RAW MATERIAL COST(Y)

Fallen by -0.05% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 15.7 times

-7What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -36.72 MM has Fallen at -198.11%

NET PROFIT(Q)

At USD -36.6 MM has Fallen at -191.3%

CASH AND EQV(HY)

Lowest at USD 587.47 MM

Here's what is working for Travere Therapeutics, Inc.

Net Sales

At USD 256.89 MM has Grown at 64.13%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow

Highest at USD 39.61 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Inventory Turnover Ratio

Highest at 15.7 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -0.05% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 25.21 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Depreciation

At USD 25.21 MM has Grown at 39.01%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (USD MM)

Here's what is not working for Travere Therapeutics, Inc.

Pre-Tax Profit

At USD -36.72 MM has Fallen at -198.11%

over average net sales of the previous four periods of USD -12.32 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -36.6 MM has Fallen at -191.3%

over average net sales of the previous four periods of USD -12.57 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 587.47 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents